Sertaconazole
Sertaconazole is a benzothiophene-substituted imidazole antifungal agent used topically for the treatment of tinea pedis (athlete's foot) and atopic dermatitis complicated by fungal infection. It exerts dual antifungal activity by inhibiting fungal cytochrome P450-mediated lanosterol demethylation (disrupting ergosterol synthesis) and by direct membrane disruption through its benzothiophene moiety. The dual mechanism provides broad-spectrum activity against dermatophytes and Candida species.
Molekularmasse
437,8000 g/mol
LogP
6,30
TPSA
55,30 Ų
Lipinski-Regel der Fünf
Bestanden
Therapeutische Bereiche
Wirkmechanismus
Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.
2D-Struktur
Cite this structure
Embed this structure
SMILES
Clc1ccc(C(Cn2ccnc2)OCc2csc3c(Cl)cccc23)c(Cl)c1
InChI
InChI=1S/C20H15Cl3N2OS/c21-14-4-5-16(18(23)8-14)19(9-25-7-6-24-12-25)26-10-13-11-27-20-15(13)2-1-3-17(20)22/h1-8,11-12,19H,9-10H2
Molecular Formula
C20H15Cl3N2OS
HBD / HBA
- / 3
Rotierbare Bindungen
6
Schwere Atome
27
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Häufig gestellte Fragen
Sertaconazole is a benzothiophene-substituted imidazole antifungal agent used topically for the treatment of tinea pedis (athlete's foot) and atopic dermatitis complicated by fungal infection. It exerts dual antifungal activity by inhibiting fungal cytochrome P450-mediated lanosterol demethylation (disrupting ergosterol synthesis) and by direct membrane disruption through its benzothiophene moiety. The dual mechanism provides broad-spectrum activity against dermatophytes and Candida species.
Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.
Yes, Sertaconazole is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201196. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 65863. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Medizinischer Haftungsausschluss
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="sertaconazole"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/sertaconazole/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/sertaconazole/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/sertaconazole/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="sertaconazole"></drugfyi-drug>